Introduction
Over the last few years, there has been a dramatic increase in severe infections caused by fungi in the immunocompromised patient; Aspergillus spp. are the most frequently implicated. The complications of therapy for haematological malignancies, solid organ transplantation, and long-term corticotherapy, are often associated with invasive aspergillosis (IA) as the result of Aspergillus fumigatus in most reported cases (85% to 90%), and also of Aspergillus flavus, Aspergillus terreus, Aspergillus nidulans and Aspergillus niger. In spite of recent progress, therapeutic failure, together with difficulty in establishing an early diagnosis, still leads to a high mortality rate, ranging from 30% to 90%. Current chemotherapy relies mainly on amphotericin B lipid complexes and triazole molecules (itraconazole, voriconazole). Recently, caspofungin, a promising new molecule that belongs to the new antifungal class, echinocandins, has proved clinically successful. However, important efforts are being made to discover other new antifungal products. 1 Benzimidazoles were first used as systemic fungicides in agriculture, then as veterinary and medical antihelmintic agents. Among them, albendazole has been used widely in the treatment of larval cestode infections, such as echinococcosis and cysticercosis. Like other members of this family, it was shown to bind to the β-tubulin subunit of microtubules, thus stopping mitosis. 2 In addition, in the 1980s and early 1990s, A. nidulans was used as a fungal model for the study of the molecular basis of the action of benzimidazoles. It was shown that Aspergillus spp. could be susceptible to some benzimidazoles, for example benomyl and carbendazim. 3 The necessity of developing new antifungal molecules, together with the time-to-market delay for new products, prompted us to investigate the potential of albendazole as an antifungal compound for medical use. Therefore, we tested the in vitro susceptibility of 49 Aspergillus spp. to albendazole, using the NCCLS reference method for conidium-forming filamentous fungi. 4 
Materials and methods

Aspergillus spp. isolates
Broth dilution antifungal susceptibility testing of drugs
The amphotericin B used in this study was Fungizone (injectable solution, Bristol-Myers Squibb, France). Albendazole was provided by Smithkline Beecham (France) as assay powder (batch OM 104243-XFP040). Drug dilutions were prepared in dimethyl sulphoxide at 100× the final concentration. For a single-drug susceptibility test, plates and stock inoculum suspensions were prepared according to the NCCLS broth microdilution method M38-P, 4 using RPMI supplemented with MOPS buffer (0.165 M, pH = 7.0 at 35°C). Results were read after a 48 h incubation at 35°C. A chequerboard broth microdilution method was adapted from Del Poeta et al. to study the amphotericin B and albendazole combination. 6 One hundred microlitres of each inoculum in RPMI (prepared according to the NCCLS M38-P method) 4 was incubated in 2 × 50 µL of a dilution of each drug (final volume = 200 µL). The end point (MIC) was read as the lowest drug concentration that could prevent any visible growth. 4 The fractional inhibitory concentration (FIC) index was then calculated, as the sum of the FICs for each of the drugs (MIC of each drug when used in combination divided by the MIC of the drug when used alone). The interaction was defined as synergic if the FIC index was < 1.0 and antagonistic if the FIC index was > 2.0, with intermediate values indicating no interaction. Both the experiments (single-drug susceptibility test, amphotericin B and albendazole combination test) were conducted twice without demonstrating a difference.
Sequencing of part of the A. flavus MB7191 β-tubulin gene
PCR amplication of part of the A. flavus MB7191 β-tubulin gene was performed on genomic DNA using the oligonucleotides ACAAgTATgTCCCTCgTgCC (position 150 of the complete cds) and ggAAgTCAgAAgCAgCCATC (position 786 of the complete cds) as primers. Sequencing was performed using the same primers.
Results and discussion
Results are summarized in Table 1 
